Background: The prevalence of allergen-induced chronic respiratory disease (CRD) is increasing annually.
Introduction
With the development of urbanization and worsening air quality, the morbidity of chronic respiratory disease (CRD) has increased annually; in the 21 st century, this major disease affects patients' quality of life globally and causes heavy societal burden. 1 A 2007 World Health Organization survey showed that > 1 billion people worldwide have CRD, which includes > 300 million patients with asthma, > 200 million patients with chronic obstructive pulmonary disease (COPD), and > 50 million patients with other types of CRD. 2 A recent European survey revealed that asthma treatment costs $22.4 billion annually. 3 Another study revealed that the projected cost of COPD in the United States in 2010 was approximately $50.0 billion. 4 Air pollution, smoking, and particularly allergens are
Methods
This study was reviewed and approved by the ethics committee of First affiliated hospital of Guangzhou Medical University, with approval number: GYFYY-2016-73. The use of human serum samples was in accordance with legislation in China and the wishes of donors, their legal guardians or next of kin, where applicable, who had offered written informed consent to using the serum samples for future unspecified research purposes.
Design and patients
This cross-sectional study included 252 adult patients (i.e., > 18 years old) with CRD. Their data were obtained from Allergy Information Repository of State Key Laboratory of Respiratory Disease (AIR-SKLRD) from January 2017 to December 2017 in China. Patients who were included had (i) recurrent wheezing, chronic cough, or limited pulmonary ventilation and (ii) respiratory physician-confirmed CRD [i.e., asthma (85 patients), COPD (98 patients), and other CRDs (69 patients)]. Patients were excluded if they were undergoing immunotherapy or had parasitic infection, food allergy, or other autoimmune diseases. The patients' sex, age, occupation, questionnaire information (including Modified Medical Research Council Dyspnea Scale [mMRC] , and COPD Assessment Test, etc.) and pulmonary function test results [forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1 percent predicted (FEV1% pred), and FVC percent predicted (FVC% pred)] were collected. There were no significant differences in age and sex among all groups ( Table 1) .
Diagnosis of disease
Bronchial asthma was diagnosed using Global Strategy for Asthma Management and Prevention (GINA) guidelines.
11 Severe asthma was defined by a clinical history of exacerbations, control situation, symptom severity within the previous 12 months, and receiving treatment with medium-or high-dose inhaled corticosteroids (ICS) and additional controller medications.
COPD was diagnosed using Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease 12 (i.e., evidence of irreversible obstructive impairment on spirometry, as defined by a postbronchodilator FEV1/FVC < 70%). Patients who exhibited FEV1% pred of ≥ 80, 50-79, 30-49, and < 30 were classified as GOLD I, GOLD II, GOLD III, and GOLD IV respectively. In addition, for the purpose of this study, COPD patients with an mMRC value ≥ 2 exhibited exertional dyspnea, Inhalant allergens have an important role in respiratory allergies, and the inhalant allergy screening test Phadiatop (Phadia, Uppsala, Sweden) gathers most common inhalant allergens into an "ImmunoCAP" (CAP) and requires only one test to determine whether a patient is allergic to common inhalant allergens. 10 However, an increased total serum IgE (tIgE) level is a common characteristic in people with atopic disorders. Therefore, we administered the Phadiatop test and the tIgE test on Chinese patients with CRD to explore the sensitization characteristics in CRD patients and the diagnostic value of allergy screening.
Clinical characteristics CRD

Total number 252
Age (y) 55.9 ± 18.8
Sex (male/female) 150/102 and patients with a CAT score ≥ 10 exhibited severe symptoms, patients with a history of acute attacks leading to hospitalization exhibited recurrent exacerbation.
Sample collection and experiment
Patient samples were obtained from the serum bank of the AIR-SKLRD. Within 2 days after the patients' first presentation and before they received any prescriptions, 5 mL venous blood was taken and centrifuged at 3000 g for 10 minutes to prepare the supernatant. It was then stored at -80°C. In this study, the Phadiatop sIgE (including fungi, pollens, insects and dust mites) and tIgE levels of the serum samples of the 252 patients with CRD were tested with the Phadia 1000 automatic allergy analyzer (ThermoFisher, Uppsala, Sweden) for in vitro diagnostic use. Samples with a Phadiatop sIgE concentration ≥ 0.35 kU/L were positive.
Data analysis
Data were processed using SPSS 20.0 statistical software (IBM Corp, Armonk, NY, USA). Normal measurement data such as age are expressed as the mean ± the standard deviation. Non-normal measurement data such as the FVC level are expressed as the median (25%, 75% range). The Mann-Whitney U test was applied to compare two-group differences and the Kruskal-Wallis test was used to compare multigroup differences. Enumeration data are expressed as the percentage. Intergroup differences were compared using the chi-square test (χ 2 ) or Fisher's exact test. Odds ratios (OR, 95% Cl) were conducted for each potential risk factor. Optimal scaling was conducted with categorical principle component analysis. Spearman rank correlation analyses were performed for correlation. A P value < 0.05 was significant. 
Results
Analysis of the overall profile of adult patients with CRD
The total positive rate of Phadiatop among Chinese adult patients with CRD was 36.1%, and asthma patients comprised the highest proportion (45. Table 2) .
Asthma patients
The total Phadiatop-positive rate among asthma patients was 45.9%. The Phadiatop-positive rates among patients with mild-to-moderate asthma and with severe asthma were 42.1% and 53.6% respectively (P > 0.05). 
Patients with COPD
The total Phadiatop-positive rate among COPD patients was 32.7%, and the Phadiatop-positive rates among GOLD I II and GOLD III IV patients were 27.8% and 37.8%, respectively (P > 0.05). 1%) . b) The correlation between the level of tIgE and Phadiatop sIgE is weaker in GOLD III IV patients (r s = 0.483, P < 0.001) than in GOLD I II patients (r s = 0.798, P < 0.001). c) The correlation between the level of tIgE and Phadiatop sIgE is weaker in patients with severe asthma (r s = 0.486, P < 0.001) than in patients with mild-to-moderate asthma (r s = 0.709, P < 0.001). d) Venn diagram of the characteristics of patients with a low Phadiatop level (≤ 10 kU/L), who exhibit a high level of tIgE (≥ 1000 kU/L). A total of 93.3% of patients had GOLD III IV disease classification. COPD = chronic obstructive pulmonary disease; CRD = chronic respiratory disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; Lg = logarithm (i.e., log 10 ); sIgE = serum immunoglobulin E; tIgE = total immunoglobulin E. 309.5; P < 0.001). The Phadiatop-positive rate among patients with recurrent exacerbation of COPD was 42.9%. Atopy maybe a risk factor for dyspnea (OR = 1.22; 95% CI, 0.95-1.75; P = 0.048) (Figure 1) . In addition, the FVC levels were lower in atopic COPD patients [2.06 L (1.83, 2.61)] than in nonatopic patients [2.63 L (2.10, 3.00)] (Mann-Whitney U, 442.5; P = 0.033) (Figure 2) . Optimal scaling analysis revealed a correlation between the tIgE level and smoking index (Cronbach's alpha = 91.1%), and a negative correlation between the tIgE level and FVC level (r s = -0.291, P = 0.009). However, no correlation existed between the tIgE level and mMRC value (r s = -0.084, P > 0.05) or CAT score (r s = -0.099, P > 0.05) (Figure  3) , and no correlation existed between the Phadiatop-positive rate and the CAT score.
Discussion
The present study investigated 252 adult patients with CRD and found that the total Phadiatop-positive rate was 36.1%, suggesting that sensitization is common in Chinese adult patients with CRD. However, allergy screening has not attracted due attention in China. Especially in basic-level hospitals or rural areas, respiratory allergies tend to be neglected, which leads to worsening symptoms and more severe chronic airway disease. 13, 14 In the future, clinicians should focus on the value of allergy screening in CRD patients.
This study also found that the Phadiatop-positive rate was highest among patients with asthma (45.9%), and the high tIgE level in patients with severe asthma, compared to patients with mild-to-moderate asthma, suggested atopy and may worsen the condition of asthmatic patients. 15 A study from the United States similarly showed that patients with severe asthma had higher concentrations of fractional exhaled nitric oxide and significantly greater sensitization to aeroallergens, compared to patients with mild-to-moderate asthma. 16 However, a review study 17 examining differences between atopic (i.e., allergic) asthma and nonatopic (i.e., intrinsic) asthma demonstrated that nonatopic asthmatics had a more severe clinical course. However, regardless of the type of asthma, pretreatment allergy screening should be considered.
We found that asthmatic office staff had the highest sensitization (68.9%), and that the tIgE level was significantly higher in asthmatic office staff than in asthmatic farmers. We speculate the high sensitization may be associated with dust mites, 10 which are the most predominant allergen in an indoor environment. A study 18 from Malaysia showed that the Der f 1 allergen protein in dust is a risk factor for "sick building syndrome" in an office environment. Therefore, with the progress in urbanization and the increase of office staff in China, 19 the morbidity of chronic airway diseases caused by allergens is expected to increase annually. This factor makes allergy screening even more urgent.
In this study, 32.7% COPD patients had atopy, and the tIgE level was significantly higher in GOLD III IV patients than in GOLD I II patients. This finding illustrates that the atopic situation of patients with COPD cannot be ignored. A study from Brazil also reported that 32.8% COPD patients presented with a positive skin prick test result. 20 Our study similarly showed that 42.9% COPD patients with recurrent exacerbation were atopic, and that atopy maybe a risk factor for dyspnea. A study 7 of 273 COPD patients similarly showed that COPD patients with increased tIgE levels have a longer history of dyspnea and more serious symptoms than patients without these features. We also found that the FVC levels were lower among atopic COPD patients than among nonatopic COPD patients. A cross-sectional case-control study of 39 COPD patients in Egypt revealed that atopic COPD patients had a longer history of illness, high smoking index, and a lower FEV1. 21 Therefore, COPD patients also need allergy screening, and atopic COPD patients with severe symptoms can attempt to combine anti-IgE antibody treatment. A study of 64 COPD patients showed a significant correlation between tIgE and the expression of the high-affinity IgE receptor on plasmocytic dendritic cells. This finding indicates anti-IgE antibody treatment is possible for severe COPD. 22 It is interesting that the optimal scaling analysis in our study revealed a correlation between the tIgE level and smoking index. Smoking may be a risk factor that increases the tIgE level. A Swiss study also demonstrated that the tIgE level of smoking COPD patients is higher than that of nonsmoking COPD patients (39.7 kU/L vs. 27.2 kU/L). 23 The present study also demonstrated a weak relationship between tIgE and Phadiatop in severe CRD patients (especially COPD). These results constitute the first detailed report of Chinese adult CRD patients.
Phadiatop only screens for sensitivity to common inhalant allergens, whereas tIgE represents the total IgE level in the serum. 10 Therefore, the levels of serum Phadiatop sIgE will not rise if the increased level of IgE in the serum of CRD patients is not caused by common inhalant allergens. Surprisingly, patients with a low Phadiatop level (≤ 10 kU/L) and a high tIgE level (93.3%) were classified as GOLD III IV patients. We did not exclude COPD patients with more sensitization to uncommon allergens, but we wish to reconsider the concert of "atopen, " which are substances-not necessarily immunogenic themselves-that are capable of deliberately directing IgE production. 24 For example, a study showed that diesel exhaust particles can increase local IgE through altering the relative amounts of five different epsilon-messenger ribonucleic acids (i.e., the code for different IgE proteins) generated by alternative splicing. 25 Patients with COPD are often exposed to a variety of dust particles in the environment. Therefore, more opportunities exist for individuals to come into contact with atopens such as diesel exhaust particles, and thereby cause tIgE production in the body. Possible implications of this finding for atopen in COPD patients require further investigation. However, the main limitation of this study was its small sample size. A larger sample size will be needed for future study to verify these findings.
Conclusion
This study showed that, in Chinese adult CRD patients, the rate of atopy is highest among asthma patients (45.9%), followed by COPD patients (32.7%) and patients with other CRDs (29.0%). The asthmatic patients who work indoors are more susceptible to allergies, and atopy correlated with COPD pulmonary function. In general, the Phadiatop test determines whether a patient is allergic by using only one CAP, which greatly reduces costs and time. However, this method is sometimes
Correlation between Phadiatop and tIgE level in patients with CRD
The Spearman analysis revealed that patients with mild-to -moderate asthma had a strong correlation between the levels of tIgE and Phadiatop sIgE (r s = 0.709, P < 0.001), but this correlation was relatively weak in severe asthma patients (r s = 0.486, P < 0.001). There was similarly a strong correlation between the level of tIgE and Phadiatop sIgE in GOLD I II patients (GOLD I II: r s = 0.798, P < 0.001 and GOLD III IV: r s = 0.483, P < 0.001), and up to 35.0% of GOLD III IV patients with a low Phadiatop level (≤ 10 kU/L) had a high level of tIgE (≥ 1000 kU/L) (Figure 4 a, b, c) . Approximately 57.1% of these patients had an mMRC value ≥ 2, a CAT score ≥ 10, or recurrent exacerbations (Figure 4d) .
